Skip to main content
Terug
Watch Compare

Aspira Women's Health Inc.

Datakwaliteit: 100%
AWHL
OTC Manufacturing Chemicals
€ 0,30
▼ € 0,01 (-3,28%)
Marktkapitalisatie: 13,05 M
Prijs
€ 0,30
Marktkapitalisatie
13,05 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -52,63% annually over 5 years
Negative free cash flow of -7,05 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 38,80%
Capital efficient — spends only 4,66% of revenue on capex

Groei

Revenue Growth (5Y)
-52,63%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-91,43%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-265,95%
Net Margin-3725,95%
Op. Margin-2307,00%

Veiligheid

Debt / Equity
N/A
Current Ratio1,39
Interest Coverage-193,00

Waardering

PE (TTM)
-1,02
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % -3726,0 -41,5
Rev Growth 5Y % -52,6 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42024 -€ 0,22 -€ 0,09 +61,4%
Q32024 -€ 0,28 -€ 0,24 +13,7%
Q22024 -€ 0,33 -€ 0,32 +1,8%
Q12024 -€ 0,32 -€ 0,38 -19,2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -91,43% Revenue Growth (3Y) -80,64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -52,63% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 343.000,0 Net Income (TTM) -12,78 M
ROE N/A ROA -208,99%
Gross Margin 1724,49% Operating Margin -2307,00%
Net Margin -3725,95% Free Cash Flow (TTM) -7,05 M
ROIC -265,95% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,39
Interest Coverage -193,00 Asset Turnover 0,06
Working Capital 1,63 M Tangible Book Value -4,69 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,02 Forward P/E N/A
P/B Ratio N/A P/S Ratio 38,05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -53,98%
Market Cap 13,05 M Enterprise Value 11,19 M
Per Share
EPS (Diluted TTM) -0,37 Revenue / Share 0,01
FCF / Share -0,16 OCF / Share -0,16
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 4,66% FCF Conversion 55,13%
SBC-Adj. FCF -7,56 M Growth Momentum -38,80

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 343.000,0 4,00 M 9,15 M 8,18 M 6,81 M
Net Income -12,78 M -13,09 M -16,69 M -27,17 M -31,66 M
EPS (Diluted) -0,37 -0,93 -1,81 -0,23 -0,28
Gross Profit 5,92 M 5,48 M 5,26 M 4,32 M 3,06 M
Operating Income -7,91 M -16,28 M -18,85 M -32,77 M -32,60 M
EBITDA — — — — —
R&D Expenses 2,88 M 3,27 M 4,04 M 5,95 M 5,31 M
SG&A Expenses — — — — —
D&A — — 199.000,0 264.000,0 302.000,0
Interest Expense -41.000,0 -33.000,0 48.000,0 17.000,0 -48.000,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5,46 M 5,49 M 6,26 M 17,37 M 41,08 M
Total Liabilities 12,39 M 8,05 M 8,63 M 10,64 M 10,91 M
Shareholders' Equity -6,93 M -2,56 M -2,37 M 6,73 M 30,17 M
Total Debt 1,77 M 2,12 M 2,27 M 3,48 M 3,70 M
Cash & Equivalents 1,76 M 1,77 M 2,60 M 13,31 M 37,18 M
Current Assets 4,06 M 4,18 M 5,28 M 16,31 M 40,01 M
Current Liabilities 3,47 M 5,47 M 5,12 M 5,78 M 7,84 M